CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN).
Authors
Laurence Albiges
Armelle Arnoux
+10 more
Hervé Baumert
Karim Bensalah
Jean-Christophe Bernard
Brigitte Duclos
Bernard Escudier
Didier Jacqmin
Brigitte Laguerre
Hervé Lang
Jean-Jacques Patard
Alain Ravaud
Publication date
1 January 2016
Publisher
'American Society of Clinical Oncology (ASCO)'
Abstract
International audienceno abstrac
Similar works
Full text
Available Versions
Hal-Diderot
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:HAL:hal-01361499v1
Last time updated on 14/04/2021